CD68 and Alzheimer disease: We observed a significant increase in the co‐labeled immunoreactivity of CD68‐IBA1 in the mPFC region of AD mice at both 10 and 16 weeks compared to the WT control group (p < 0.0001, Figure 5A,a1) while treatment with both hNSC‐ and iMGL‐derived EVs significantly reduced microglial activation in the mPFC region of 5xFAD mice compared to vehicle‐treated AD mice at the 10 week post‐treatment time (p < 0.001 and 0.0001, respectively).